Autoantibody-negative autoimmune hepatitis

Digestive Diseases and Sciences

Volumn 57, Issue 3, 2012, Pages 610-624

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoantibody negative; Autoimmune hepatitis; Cryptogenic hepatitis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; IMMUNOGLOBULIN G; PREDNISONE;

ACUTE HEPATITIS; AUTOIMMUNE HEPATITIS; AWARENESS; CELL INFILTRATION; CHRONIC HEPATITIS; COMORBIDITY; HISTOPATHOLOGY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LIVER TRANSPLANTATION; NECROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; SURVIVAL; BLOOD; EPIDEMIOLOGY; IMMUNOLOGY; RISK FACTOR;

AUTOANTIBODIES; HEPATITIS, AUTOIMMUNE; HEPATITIS, CHRONIC; HUMANS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84859487734     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-2017-z     Document Type: Review

References (200)

1. Manns MP, Czaja AJ, Gorham JD, et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213.
2. Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol. 2007;1:129-143.
3. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938. (Pubitemid 29514229)
4. Kanzler S, Löhr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001;39:339-341, 344-338.
5. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161-167.
6. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology. 2008;48: 1540-1548.
7. Czaja AJ. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology. 2011;140:1472-1480.
8. Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421-3438.
9. Johnson PJ, McFarlane IG, McFarlane BM, Williams R. Autoimmune features in patients with idiopathic chronic active hepatitis who are seronegative for conventional auto-antibodies. J Gastroenterol Hepatol. 1990;5:244-251. (Pubitemid 20375184)
10. Czaja AJ. Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci. 2011;56: 545-554.
11. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996;24:1068-1073. (Pubitemid 26365905)
12. Cançado EL, Abrantes-Lemos CP, Vilas-Boas LS, Novo NF, Carrilho FJ, Laudanna AA. Thermolabile and calcium-dependent serum factor interferes with polymerized actin, and impairs anti-actin antibody detection. J Autoimmun. 2001;17:223-228. (Pubitemid 33108758)
13. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259-264. (Pubitemid 34791458)
14. Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41:677-683. (Pubitemid 39297806)
15. Chretien-Leprince P, Ballot E, Andre C, et al. Diagnostic value of anti-F-actin antibodies in a French multicenter study. Ann N Y Acad Sci. 2005;1050:266-273. (Pubitemid 41129444)
16. Torres-Collado AX, Czaja AJ, Gelpí C. Anti-tRNP(ser)sec/SLA/ LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. Liver Int. 2005;25:410-419.
17. Frenzel C, Herkel J, Lüth S, Galle PR, Schramm C, Lohse AW. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol. 2006;101:2731-2736. (Pubitemid 44902644)
18. Granito A, Muratori L, Muratori P, et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol. 2006;59:280-284. (Pubitemid 43344890)
19. Guéguen P, Dalekos G, Nousbaum JB, et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol. 2006;26:495-505.
20. Aubert V, Pisler IG, Spertini F. Improved diagnoses of autoimmune hepatitis using an anti-actin ELISA. J Clin Lab Anal. 2008;22:340-345.
21. Hausdorf G, Roggenbuck D, Feist E, et al. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA-revival of a disease-activity marker in autoimmune hepatitis. Clin Chim Acta. 2009;408:19-24.
22. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010;139:58-72.
23. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem. 2005;40:127-164. (Pubitemid 43588722)
24. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc. 1990;65:23-30. (Pubitemid 20061922)
25. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology. 1993;104:1755-1761. (Pubitemid 23235469)
26. Kaymakoglu S, Cakaloglu Y, Demir K, et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol. 1998;28:78-83. (Pubitemid 28122503)
27. Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroidresponsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52:2433-2437. (Pubitemid 47246512)
28. Potthoff A, Deterding K, Trautwein C, et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol. 2007;45:15-19. (Pubitemid 46202716)
29. Heringlake S, Schütte A, Flemming P, Schmiegel W, Manns MP, Tillmann HL. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol. 2009;47:417-423.
30. Treichel U, Poralla T, Hess G, Manns M, Meyer zum Büschenfelde KH. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology. 1990;11: 606-612. (Pubitemid 20151738)
31. Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology. 1992;16:892-898.
32. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012;32:85-92.
33. Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol. 2008;23:1410-1414.
34. Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci. 1986;31:705-711. (Pubitemid 16059702)
35. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology. 1993;105:1522-1528. (Pubitemid 23315330)
36. Nezu S, Tanaka A, Yasui H, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol. 2006;21:1448-1454. (Pubitemid 44154715)
37. Mishima S, Omagari K, Ohba K, et al. Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study. Hepatogastroenterology. 2008;55:221-227. (Pubitemid 351462195)
38. Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol. 2008;42:1047-1053.
39. O'Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology. 2008;48:550-556.
40. Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol. 2008;43:951-958.
41. Kanda T, Yokosuka O, Hirasawa Y, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology. 2005;52: 1233-1235. (Pubitemid 40942222)
42. Fujiwara K, Yasui S, Tawada A, Fukuda Y, Nakano M, Yokosuka O. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis. Liver Int. 2011;31:1013-1020.
43. Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults: experience in a Japanese center. Hepatol Res. 2011;41:133-141.
44. Bernal W, Ma Y, Smith HM, Portmann B, Wendon J, Vergani D. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol. 2007;47:664-670. (Pubitemid 47503423)
45. Hiramatsu A, Takahashi S, Aikata H, et al. Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center. J Gastroenterol Hepatol. 2008;23:1216-1222.
46. Mehendiratta V, Mitroo P, Bombonati A, et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2009;7:98-103.
47. Miyake Y, Yamamoto K. Current status of autoimmune hepatitis in Japan. Acta Med Okayama. 2008;62:217-226.
48. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40: 646-652. (Pubitemid 38367787)
49. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29:816-823.
50. Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci. 1998;43:2149-2155.
51. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824-1832. (Pubitemid 24002801)
52. Kanda T,YokosukaO,HirasawaY, et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology. 2005;52:1233-1235. (Pubitemid 40942222)
53. Czaja AJ, Carpenter HA. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci. 1996;41:305-314. (Pubitemid 26088706)
54. Czaja AJ. Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis. Dig Dis Sci. 1998;43:1725-1731. (Pubitemid 28381583)
55. Brandhagen DJ, Fairbanks VF, Batts KP, Thibodeau SN. Update on hereditary hemochromatosis and the HFE gene. Mayo Clin Proc. 1999;74:917-921.
56. Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet. 1998;352:26-29. (Pubitemid 28306562)
57. Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology. 2002;122:881-888. (Pubitemid 34267270)
58. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol. 2004;2:107-112. (Pubitemid 38180463)
59. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25:263-270. (Pubitemid 36546352)
60. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625-631. (Pubitemid 38834047)
61. Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007;5:898-907. (Pubitemid 47127038)
62. Powell EE, Jonsson JR, Clouston AD. Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis. 2010;28:186-191.
63. Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009;8:346-352.
64. Akbar HO. Cryptogenic or autoimmune hepatitis. Saudi J Gastroenterol. 2002;8:99-101.
65. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169-176. (Pubitemid 351975541)
66. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269-291.
67. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820-833.
68. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16:876-883.
69. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990;30:358-363. (Pubitemid 20274115)
70. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 2000;47:63-83. (Pubitemid 30394533)
71. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448-453.
72. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102: 1005-1012. (Pubitemid 46698236)
73. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198-1206.
74. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215-221.
75. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol. 1999;30:131-141. (Pubitemid 29023662)
76. Cattan P, Berney T, Conti F, et al. Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transpl Int. 2002;15:34-38. (Pubitemid 36055897)
77. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22: 145-155. (Pubitemid 34496468)
78. Núñez-Martínez O, De la Cruz G, Salcedo M, et al. Liver transplantation for autoimmune hepatitis: fulminant versus chronic hepatitis presentation. Transplant Proc. 2003;35:1857-1858. (Pubitemid 37093740)
79. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 2004;18:62-69. (Pubitemid 38195546)
80. Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant Proc. 2007;39:1166-1170.
81. Schramm C, Bubenheim M, Adam R, et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl. 2010;16:461-469.
82. Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 2008;14:1281-1286.
83. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis. 2002;22:379-386.
84. Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis. 2009;29:286-296.
85. Duclos-Vallée JC, Yilmaz F, Johanet C, et al. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin Transplant. 2005;19:591-599. (Pubitemid 41341689)
86. Charlton MR, Kondo M, Roberts SK, Steers JL, Krom RA, Wiesner RH. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg. 1997;3:359-364. (Pubitemid 27310174)
87. Ku NO, Gish R, Wright TL, Omary MB. Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med. 2001; 344:1580-1587. (Pubitemid 32479910)
88. Syn WK, Nightingale P, Gunson B, Hubscher SG, Neuberger JM. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl. 2007;13:984-989. (Pubitemid 47163190)
89. Sanjeevi A, Lyden E, Sunderman B, Weseman R, Ashwathnarayan R, Mukherjee S. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients. Transplant Proc. 2003;35:2977-2980.
90. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transplant. 2010;16:431-439.
91. Heneghan MA, Zolfino T, Muiesan P, et al. An evaluation of long-term outcomes after liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2003;9:921-928. (Pubitemid 37098840)
92. McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother. 1999;53:255-263.
93. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113-128.
94. Lapierre P, Béland K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res. 2007;149:107-113. (Pubitemid 46275575)
95. Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol. 2008;14:3306-3312.
96. Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144-2161.
97. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394-401. (Pubitemid 29113226)
98. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut. 1998;42:721-726. (Pubitemid 28261064)
99. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut. 1998;42:721-726. (Pubitemid 28261064)
100. Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med. 2002;13:293-303. (Pubitemid 34812340)
101. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:413-419. (Pubitemid 34160769)
102. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol. 1999;31:635-640. (Pubitemid 29487684)
103. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity. 2002;35:475-483. (Pubitemid 36321887)
104. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein recep tor in type 1 autoimmune hepatitis. Dig Dis Sci. 1996;41: 1733-1740. (Pubitemid 26319747)
105. McFarlane BM, McSorley CG, Vergani D, McFarlane IG, Williams R. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol. 1986;3:196-205. (Pubitemid 17173105)
106. Meyerzum Büschenfelde KH, Treichel U, Löhr H, Fleischer B, Poralla T. Human asialoglycoprotein receptor as an autoantigen in chronic hepatitis. Immunol Res. 1991;10:497-502.
107. Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Büschenfelde KH, Poralla T. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol. 1993; 19:55-63. (Pubitemid 23338011)
108. Dejica D, Treichel U, Pár A, Chira O, Meyer zum Büschenfelde KH. Anti asialoglycoprotein receptor antibodies and soluble interleukin-2 receptor levels as marker for inflammation in autoimmune hepatitis. Z Gastroenterol. 1997;35:15-21. (Pubitemid 27064433)
109. Yoshioka M, Mizuno M, Morisue Y, et al. Anti-asialoglycoprotein receptor autoantibodies, detected by a capture-immunoassay, are associated with autoimmune liver diseases. Acta Med Okayama. 2002;56:99-105.
110. Hilgard P, Schreiter T, Stockert RJ, Gerken G, Treichel U. Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis. Hepatology. 2004;39:1398-1407. (Pubitemid 38569062)
111. Husa P, Chalupa P, Stroblová H, Husová L, Slesinger P, Zajíc J. Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients. Acta Virol. 2001;45:7-11. (Pubitemid 32448412)
112. Sasaki M, Yamauchi K, Tokushige K, et al. Clinical significance of autoantibody to hepatocyte membrane antigen in type 1 autoimmune hepatitis. Am J Gastroenterol. 2001;96:846-851. (Pubitemid 32240743)
113. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet. 1984;2:954-956. (Pubitemid 15201176)
114. Hajoui O, Martin S, Alvarez F. Study of antigenic sites on the asialoglycoprotein receptor recognized by autoantibodies. Clin Exp Immunol. 1998;113:339-345. (Pubitemid 28410556)
115. Schreiter T, Liu C, Gerken G, Treichel U. Detection of circulating autoantibodies directed against the asialoglycoprotein receptor using recombinant receptor subunit H1. J Immunol Methods. 2005;301:1-10. (Pubitemid 40961970)
116. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology. 1993;17:411-417. (Pubitemid 23072815)
117. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology. 1995;108:1159-1166.
118. Bansi D, Chapman R, Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol. 1996;24:581-586. (Pubitemid 26167584)
119. Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology. 1997;25:1105-1107. (Pubitemid 27199935)
120. Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol. 2003;37: 315-329. (Pubitemid 37158995)
121. De Riva V, Celadin M, Pittoni M, Plebani M, Angeli P. What is behind the presence of anti-neutrophil cytoplasmatic antibodies in chronic liver diseasě Liver Int. 2009;29:865-870.
122. Terjung B, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 2000;119:310-322. (Pubitemid 30621981)
123. Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"? Clin Rev Allergy Immunol. 2009;36:40-51.
124. Sir JU, Kim TY. Is ANCA really related to chronic liver diseasě Liver Int. 2010;30:157-158; author reply 158-159.
125. Dalekos GN, Tsianos EV. Anti-neutrophil antibodies in chronic viral hepatitis. J Hepatol. 1994;20:561. (Pubitemid 24146376)
126. Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116:643-649. (Pubitemid 29106772)
127. Muratori L, Sztul E, Muratori P, et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology. 2001;34:494-501. (Pubitemid 32786639)
128. Martini E, Abuaf N, Cavalli F, et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology. 1988;8:1662-1666. (Pubitemid 19021905)
129. Lenzi M, Manotti P, Muratori L, et al. Liver cytosolic 1 antigenantibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut. 1995;36:749-754.
130. Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology. 1995;21:58-62.
131. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity. 2004;37:195-201. (Pubitemid 39162676)
132. Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet. 1994;344:578-581.
133. Durazzo M, Philipp T, Van Pelt FN, et al. Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology. 1995;108:455-462.
134. Strassburg CP, Obermayer-Straub P, Alex B, et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology. 1996;111: 1576-1586. (Pubitemid 26404222)
135. Csepregi A, Nemesánszky E, Luettig B, Obermayer-Straub P, Manns MP. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity. Am J Gastroenterol. 2001;96:910-911. (Pubitemid 32240756)
136. Obermayer-Straub P, Manns MP. Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol Biol Rep. 1996;23:235-242. (Pubitemid 27153046)
137. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology. 1997;26:1054-1066. (Pubitemid 27415802)
138. Fusconi M, Cassani F, Zauli D, et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods. 1990;130:1-8. (Pubitemid 20190482)
139. Jaskowski TD, Konnick EQ, Ashwood ER, Litwin CM, Hill HR. Prevalence of IgG autoantibody against F-actin in patients suspected of having autoimmune or acute viral hepatitis. J Clin Lab Anal. 2007;21:249-253. (Pubitemid 47175026)
140. Martinez-Neira R, dos Remedios CG, Mackay IR. An actinmyosin functional assay for analysis of smooth muscle (antimicrofilament) autoantibodies in human plasma. J Immunol Methods. 2008;338:63-66.
141. Soares A, Cunha R, Rodrigues F, Ribeiro H. Smooth muscle autoantibodies with F-actin specificity. Autoimmun Rev. 2009; 8:713-716.
142. Villalta D, Bizzaro N, Da Re M, Tozzoli R, Komorowski L, Tonutti E. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders. Autoimmunity. 2008;41:105-110.
143. Zamanou A, Samiotaki M, Panayotou G, Margaritis L, Lymberi P. Fine specificity and subclasses of IgG anti-actin autoantibodies differ in health and disease. J Autoimmun. 2003;20:333-344. (Pubitemid 36677525)
144. Lidman K, Biberfeld G, Fagraeus A, et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol. 1976;24:266-272.
145. Oikonomou KG, Zachou K, Dalekos GN. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev. 2011;10:389-396.
146. Renaudineau Y, Dalekos GN, Guéguen P, Zachou K, Youinou P. Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol. 2008;34:321-325.
147. Volta U. Liver dysfunction in celiac disease. Minerva Med. 2008;99:619-629.
148. Mackay IR, Larkin L, Burnet FM. Failure of autoimmune antibody to react with antigen prepared from the individual's own tissues. Lancet. 1957;273:122-123.
149. Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet. 1959;1: 65-69.
150. Hopf U, Meyer zum Büschenfelde KH, Arnold W. Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med. 1976;294:578-582.
151. Frazer IH, Kronborg IJ, Mackay IR. Antibodies to liver membrane antigens in chronic active hepatitis (CAH). II. Specificity for autoimmune CAH. Clin Exper Immunol. 1983;54:213-218. (Pubitemid 13052127)
152. CzajaAJ,Morshed SA, Parveen S,NishiokaM.Antibodies to singlestranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology. 1997;26:567-572. (Pubitemid 27392345)
153. Czaja AJ, Ming C, Shirai M, Nishioka M. Frequency and significance of antibodies to histones in autoimmune hepatitis. J Hepatol. 1995;23:32-38.
154. Chen M, Shirai M, Czaja AJ, et al. Characterization of antihistone antibodies in patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:483-489.
155. Li L, Chen M, Huang DY, Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type I. J Gastroenterol Hepatol. 2000;15:1176-1182.
156. Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci. 2003;48:1658-1664. (Pubitemid 36936707)
157. Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology. 1994;107:200-207. (Pubitemid 24195363)
158. Toh BH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol. 1979;38:621-628. (Pubitemid 10161320)
159. Fusconi M, Vannini A, Dall'Aglio AC, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2005;22:951-955. (Pubitemid 41634876)
160. Montano-Loza A, Czaja AJ, Carpenter HA, et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity. 2006;39:341-348. (Pubitemid 44203510)
161. Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol. 1998;93:1334-1339. (Pubitemid 29076937)
162. Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol. 2003;132:473-476. (Pubitemid 36713954)
163. Czaja AJ, Shums Z, Donaldson PT, Norman GL. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. Dig Dis Sci. 2004;49:611-618. (Pubitemid 38992549)
164. Parveen S,MorshedSA,Arima K, et al.Antibodies toRo/La,Cenp-B, and snRNPs antigens in autoimmune hepatitis of NorthAmerica versus Asia: patterns of
165. Djilali-Saiah I, Lapierre P, Vittozi S, Alvarez F. DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. J Immunol. 2002; 169:4889-4896. (Pubitemid 35217153)
166. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology. 2004;39:1066-1074. (Pubitemid 38428946)
167. Lapierre P, Béland K, Djilali-Saiah I, Alvarez F. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun. 2006;26:82-89. (Pubitemid 43138878)
168. Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409-1422. (Pubitemid 351831496)
169. Czaja AJ. Animal models of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2010;4:429-443.
170. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224-1231. (Pubitemid 32319165)
171. Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2007;53:43-78. (Pubitemid 46978249)
172. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2010;34:7-14.
173. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(?)CD25(?) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31-37. (Pubitemid 39005149)
174. Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4? CD25? regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63-71. (Pubitemid 41008667)
175. Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4?CD25? regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484-4491. (Pubitemid 44264429)
176. Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008;47:581-591. (Pubitemid 351280726)
177. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103:264-274.
178. al-Wabel A, al-Janadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic active hepatitis. J Allergy Clin Immunol. 1993;92:902-908. (Pubitemid 23361631)
179. Schlaak JF, Löhr H, Gallati H, Meyer zum Büschenfelde KH, Fleischer B. Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin Exp Immunol. 1993;94:168-173. (Pubitemid 23308384)
180. Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 1995;20:23-27.
181. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851-856. (Pubitemid 29458270)
182. Czaja AJ, Cookson S, Constantini PK, et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117: 645-652. (Pubitemid 29409251)
183. Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci. 2000;45:1028-1035. (Pubitemid 30238270)
184. Chen W, Perruche S, Li J. CD4?CD25? T regulatory cells and TGF-beta in mucosal immune system: the good and the bad. Curr Med Chem. 2007;14:2245-2249. (Pubitemid 47570685)
185. Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z Gastroenterol. 2007;45:63-70. (Pubitemid 46202722)
186. Löhr H, Manns M, Kyriatsoulis A, et al. Clonal analysis of liverinfiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol. 1991;84:297-302.
187. Löhr H, Treichel U, Poralla T, Manns M, Meyer zum Büschenfelde KH. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin Exp Immunol. 1992;88:45-49.
188. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J. 1998;12:1255-1265. (Pubitemid 28475568)
189. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med. 1999;341:2068-2074. (Pubitemid 30035957)
190. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225-232. (Pubitemid 32677377)
191. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002; 6:727-737.
192. Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol. 2006;2:33-48. (Pubitemid 44355594)
193. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379-388.
194. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658-664. (Pubitemid 34183971)
195. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol. 1997;92:2197-2200.
196. Bittencourt PL, Goldberg AC, Cançado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999;94:1906-1913. (Pubitemid 29315909)
197. Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol. 2006;45:844-850. (Pubitemid 44646681)
198. Muratori P, Czaja AJ, Muratori L, et al. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci. 2007; 52:179-184. (Pubitemid 46122064)
199. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953-955. (Pubitemid 47163184)
200. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958-976.